StockNews.AI
ELAN
StockNews.AI
75 days

Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

1. 9 in 10 U.S. dogs are reported to be itchy by owners. 2. Zenrelia provides a cost-effective solution for dog itch relief. 3. Veterinarians increasingly frustrated with dog itch as top treatment issue. 4. Pet owners spend significantly more during allergy season for treatments. 5. Half of dog owners with itchy pets consider switching veterinarians.

14m saved
Insight
Article

FAQ

Why Bullish?

The widespread recognition of itchiness in dogs and the introduction of Zenrelia positions Elanco strongly. Historical increases in pet health product demand during allergy seasons showcase potential for revenue growth.

How important is it?

The report highlights the need for solutions like Zenrelia, aligning with market demand. Coupled with the emotional aspect of pet ownership, this will drive sales growth.

Why Short Term?

Immediate impact likely as pet owners seek solutions for seasonal allergies. Historical trends show quick spikes in product sales during heightened allergy seasons.

Related Companies

Elanco Animal Health Reports on America's Itchy Dogs

GREENFIELD, Ind., June 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today released a new report highlighting the significance of America's Itchy Dogs and the impact itch has on dogs, their owners, and veterinarians.

The first-of-its-kind report includes findings from multiple surveys of pet owners, as well as veterinarians, and reveals startling details on how badly dogs around the country are itching for relief and cost-effective, long-lasting solutions.

With Zenrelia™ (ilunocitinib tablets) now widely available as a once-daily, cost-effective solution, veterinarians and dog owners have another option to help dogs get back to normal.

Related News